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INTERKEUKIN I ß ,  TUMOUR NECROSIS 
FACTOR-a AND INTERLEUKIN 1 RECEPTOR
ANTAGONIST IN NEWLY DIAGNOSED 
INSULIN-DEPENDENT DIABETES MELLITUS: 
COMPARISON TO LONG-STANDING DIABETES
AND HEALTHY INDIVIDUALS
Mihai G. Netea,1,3 Nicolae Hancu,1 Willem L. Blok,3 
Paula Grigorescu-Sido,2 Lenuta Popa,2 Victor Popa,2 
Jos W. M. van der Meer3
Interleukin 1 beta (IL-1) and tumour necrosis factor alpha (TNF) are important for the beta 
cell lysis in insulin-dependent diabetes mellitus (IDDM), while IL-1 receptor antagonist (IL-lra) 
is considered protective by blocking the effects of IL-1. Serum concentrations and ex-vivo 
production of IL-1, TNF and IL-lra were examined in 10 newly diagnosed IDDM (ND-IDDM) 
patients, and compared with 11 long-standing IDDM (LS-IDDM) patients and 14 healthy 
volunteers. Ex-vivo LPS-stimulated production of IL-1 in ND-IDDM patients was significantly 
increased compared with LS-IDDM patients and healthy controls, while TNF and IL-lra 
synthesis did not differ significantly. IL-lra/IL-1 ratio was significantly decreased in 
ND-IDDM, and returned to normal values in the LS-IDDM group. Circulating concentrations 
of IL-lra in LS-IDDM patients were increased. These data suggest a proinflammatory 
imbalance in ND-IDDM patients and this may play an important role in beta cell loss.
ip 1997 Academic Press Limited
Insulin-dependent diabetes mellitus (IDDM) is an 
autoimmune disease in which beta cell lysis is the 
central event.1 In this process, the pro-inflammatory 
cytokines interleukin 1 beta (IL-1) and tumour necrosis 
factor alpha (TNF) are thought to play an important 
role. In vitro studies have shown that IL-1 interferes
insulin secretion from pancreatic beta cells2 
and has a lytic effect on islet cells.3 Intraperitoneal 
administration o f  IL-1 accelerates the onset of IDDM  
in the BB-rat model,4 and induces hyperglycemia 
and hypoinsulinemia in normal Wistar Kyoto rats.5 
Although TNF by itself is not cytotoxic to the beta cell, 
it strongly potentiates the action of IL-1/’ Interleukin 
1 receptor antagonist (IL-lra), the naturally occurring
From the 'Diabetes Center and Clinic, Str. Clinicilor nr. 2, 3400 
Cluj-Napoca, Romania; 3Pediatric Clinic no. 1» Str. M olilor nr. 
68, 3400 Cluj-Napoca, Romania; ’Department o f  Internal 
Medicine, University Hospital Nijmegen, Geert Grooteplein Zuid 
8, 6500 HB Nijmegen, The Netherlands 
Correspondence to: Jos W. M. van der Meer, Department oflnternal 
Medicine, University Hospital Nijmegen, Geert Grooteplein Zuid 
8, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 
Received 7 M ay 1996; accepted for publication 16 September 1996 
iO 1997 Academic Press Limited 
1043-4666/97/040284 +  4 $25.00/0/ck960165
KEY W ORDS: insulin-dependent diabetes mellitus/interleukin-1/ 
tumour necrosis factor/interleukin-1 receptor antagonist
antagonist of IL-1, was shown to protect beta-cells 
against the deleterious effects o f  IL-1,7 and to delay the 
onset of diabetes in BB-rats.8
The aim o f the present study was to assess the 
pro- and anti-inflammatory cytokine production in 
IDDM patients. We investigated both circulating and 
ex-vivo produced IL-lß, T N F a and IL-ra in newly- 
diagnosed IDDM  (N D -ID D M ) and long-standing 
IDDM (LS-IDDM) patients, and we compared them 
with a group of healthy volunteers.
RESULTS
Circulating concentrations o f  fL~t, TNF and 
IL-lra
IL-1 concentrations were detectable in serum of  
only 2 o f  10 healthy volunteers (4.2 and 5.6 
4 of 10 N D -ID D M  patients (range 5 13.5 pg/ml) and 
1 of 11 LS-IDDM patients (5.2 pg/ml). Circulating 
concentrations o f  T N F were below detection 
Circulating IL-lra concentrations did not differ 
between control individuals (234 +  216 pg/ml) and 
N D -ID D M  patients (184 +  158 pg/ml), but were
in LS-IDDM patients (461 ±  
167 pg/ml, P  <  0.05) (Fig. 1A).
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Figure 1. Circulating concentrations of interleukin I receptor 
antagonist (IL-lra) ( □ )  in healthy controls, newly diagnosed IDDM  
patients and long-standing IDDM  patients (A) and ex-vivo production 
of interleukin-1 beta (IL-1) ( ■ )  and tumour necrosis factor alpha
(TNF) ( ■ )  after stimulation with LPS (1 0 ng/ml) (B). 
Results expressed as mean ±  standard deviation. *P  <  0.05.
Ex vivo LPS-stimulated production o f  IL-1 in 
healthy volunteers was 2.1 ±  1.0 ng/ml. In ND-IDDM  
patients the release of IL-1 was significantly increased
, whereas IL-1 production(3.2 ±  1.2 ng/ml, P <  0. 
in LS-IDDM patients did not differ significantly from 
the control group ( 1.4 ±  1.0 ng/ml, P >  0.05) (Fig. 1B).
o f  T N F was 3.1 ±  1.8 ng/ml 
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DISCUSSION
IDDM  is characterized by mononuclear cell 
infiltration of the islets of Langerhans, associated with 
a selective ß-cell lysis. Recent studies suggest that the 
pro-infiammatory cytokine IL-1 plays a major role in 
the inhibition of insulin secretion2 and in the lysis
of ß-cells.3 TNF, another major pro-infiammatory 
cytokine, strongly increases the effects of IL-l." In the 
present study we show that non-ketotic N D-IDD M  
patients have an increased production capacity o f  
IL-1 and a tendency towards higher synthesis of TNF  
when compared with healthy controls. Apparently, the 
cytokine production capacity returns to normal values 
with longer duration of illness.
Contrasting data are available in the literature 
regarding the pro-infiammatory cytokine production 
capacity o f  IDDM done in
monocytes of N D -ID D M  patients did not find any
ünce in IL-1 and TNF production when compared 
with the controls.9,10 However, the longer duration 
of diabetes (68.6 days) in the N D -ID D M  patients 
investigated by Molvig and colleagues,1’ and the use of 
silica as a stimulus for cytokine production by Luger 
et makes difficult the comparison of these studies 
with the present data. In contrast, other investigators 
have found an increased production of cytokines after 
in vitro stimulation of blood mononuclear cells of  
ND-IDDM  patients 
system. H owever, 
with the data from the literature, it is also important
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TABLE 1. IDDM
N D -ID D M  LS-IDDM  Controls
Number
Sex (M /F)
10 11 14
6/4 6/5 8/6
Age (years) 21 (13-23) 27 (12-35) 22 (19 27)
ID D M  duration 3.4 days 4,7 years
Insulin (IU /day) 27.4 ±  12.9 49.9 ±  17.4
Fasting blood glucose (mg/dl) 260 ±  70 242 +  89 94 ±  16
HBAi (%) 9.4 ± 1 . 6  8.6 +  1.1 7.1 ±  0.3
*Data are given as mean ±  SD, with the exception of age which is given as median (interval).
it is possible that the “normal” production capacity 
with longer duration of illness represents a decrease 
of genetically increased production capacity. This 
hypothesis is sustained by other studies showing a 
decreased cytokine production capacity in patients
Alternatively, the increasedwith LS-IDDM. 15,16
process in the pancreas, this pro-inflammatory status is 
reversed.
MATERIALS AND METHODS
capacity found can be due to the disease process itself 
rather than to genetics.
To the best o f  the authors’ knowledge, this study 
is the first to assess the ex vivo IL-lra production 
capacity o f  IDDM  patients. The stimulated production 
of IL-lra did not differ between healthy individuals 
and ND- or LS-IDDM patients. The decrease of 
IL-lra/IL-1 ratio in N D -ID D M  patients sustains 
the hypothesis of Mandrup-Poulsen et al. that the 
imbalance between IL-1 and IL-lra is central in the 
autoaggressive reaction against beta cell.17 A similar 
imbalance of IL-lra/IL-1 ratio was recently found in
,  IKpatients with chronic inflammatory bowel diseases, 
in rheumatoid synovium19 and in the synovial fluid 
of Lyme arthritis patients.20
Circulating concentrations o f  TN F were below the 
detection limit, as was the case for circulating IL-1 in 
the majority of samples. The differences in serum 
concentrations o f  IL-lra are difficult to explain. While 
in newly diagnosed IDDM  patients IL-lra concen­
trations were similar to healthy individuals, we found 
significantly increased concentrations in long-standing 
IDDM. This is supported by the finding of higher 
I L-11 ra circulating concentrations in IDDM  
with the A1/A2 genotype for IL-lra gene when
with control subjects with the same 
genotype.21 Thus, it seems that differences in circulating 
IL-lra concentrations do appear in the course of  
IDDM , and a correlation o f  these modifications with 
certain genotypes can not be excluded.
In conclusion, we have found an increased 
IL-1 production capacity and a decreased IL-lra/ 
IL-1 ratio in newly diagnosed IDDM  patients, 
which argues for an imbalance in favour o f  the 
pro-inflammatory cytokines. This may be important 
in the pathophysiology o f  the beta cell lysis. During 
the evolution o f  the disease, probably after all the 
ß-cells are lysed with a cessation of the inflammatory
Ten ND-IDD M  patients, 11 LS-IDDM patients and 14 
healthy individuals were studied. The clinical characteristics 
of the patients are given in Table 1. Written consent was 
given by each individual participating in the study. Both 
groups o f  IDDM patients were non-ketotic at the time of  
sampling. The C-peptide plasma concentration was tested in 
the IDDM patients and in all of them was below 0.1 nmol/1. 
Any sign of infection and/or other inflammatory diseases 
served as an exclusion criteria. The newly diagnosed IDDM  
patients were tested within 5 days from diagnosis, while each 
of the long-standing IDDM patients had more than 1 year 
duration of the disease.
Blood has been drawn from the cubital vein in 4-ml 
sterile tubes containing 48 j.l 1 EDTA (Vacutainer 
Becton and •d, NJ). Plasma was 
separated and stored at ~-20"C until the assays were
between 7 andwereperformed. All
8 a.m. The ex vivo lipopolysacchar 
production was assesed as described elsewhere.” Briefly, the
s of 4 ml as describedblood was drawn in another two 
above. The tubes were incubated 24 h at 37 C with the 
addition of 50 jj.1 o f lipopolysaccharide (LPS) (LPS; E. colt 
serotype 055:B5, Sigma Chemical Co., St Louis, MO) 
containing 0.8 mg/ml (final concentration of LPS: 10 |.ig/ml). 
After 24 h, the tubes were centrifuged, plasma was collected 
and stored at — 20"C until assay.
Measurement o f IL-1 ß, IL-lra and TNF alpha. IL,-Iß 
and IL-lra concentrations were measured as duplicates using 
a quantitative enzyme immunoassay (Quantikinc™, R&D 
Systems Europe, Abingdon, UK) according to the instruc­
tions of the manufacturer, 
monoclonal antibody bound to a solid phase, and a specific 
polyclonal antibody conjugated to horseradish peroxidase. 
The specified detection limit for IL-1 ß was 3.9 pg/ml, and 
for IL-lra was 46.9 pg/ml. TNF alpha was determined by 
an ELISA kit (Boehringer Mannheim, Germany), using
two mouse monoclonal
epitopes of
against two
human TN Fa. 
detection limit was 32 pg/ml. Samples from 5 ND-IDDM , 4 
LS-IDDM and 10 healthy controls were also tested using a 
radio-immunoassay method, as described previously.'’
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Statistical analysis
Cytokine concentrations are expressed as mean ±  SD.
erences the groups were ana using the
Kruskal Wallis test with chi-square approximation. Differ­
ences were considered significant when P value was below
0.05.
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